Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients

Yiqun Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoge Kou(First Affiliated Hospital of Xinxiang Medical University), Ning Li(Zhengzhou University), Shu Zhang(Tianjin University of Technology), Yanfeng Wang(Beijing Institute of Technology), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Haijun Zhong(Cancer Hospital of Chinese Academy of Medical Sciences), Xianli Yin(Central South University), Yunpeng Liu(Shenyang Institute of Automation), Zhixiang Zhuang(Soochow University), Xinjun Liang(Hubei Cancer Hospital), Qingxia Fan(First Affiliated Hospital of Zhengzhou University)
Chinese Medical Journal
March 3, 2022
10.1097/cm9.0000000000002054
Cited by 6

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
|Nature Medicine|2023|541
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508